Sarepta Therapeutics (NASDAQ: SRPT) suffered a devastating blow on Monday, June 16 when its stock plummeted 42% following news of a second patient death linked to its Duchenne muscular dystrophy gene ...

Sarepta’s restructuring plan aims to save about $400 million annually starting in 2026. To achieve this target, the company has decided to lay off 36% of its workforce — around 500 employees — which ...

Members of Congress have traded $SRPT stock 1 times in the past 6 months. Of those trades, 0 have been purchases and 1 have been sales. Here’s a breakdown of recent ...

Shares of Sarepta Therapeutics SRPT plunged nearly 24% last week after the company reported the death of a patient following treatment with Elevidys, its one-shot gene therapy for Duchenne muscular ...

On Sunday, Sarepta provided a safety update regarding Elevidys (delandistrogene moxeparvovec-rokl), the only approved gene therapy for patients with Duchenne muscular dystrophy, and steps the company ...

Sarepta Therapeutics ( (SRPT)) has issued an announcement. On December 10, 2025, Sarepta Therapeutics entered into exchange agreements to refinance approximately $291.4 million of its 1.25% ...

Sarepta Pharmaceuticals Inc (NASDAQ: SRPT) stock is plummeting down, down 31.4% at $16.77 at last glance. Though the biotech company reported an impressive revenue beat, a wider-than-expected loss per ...

Sarepta Therapeutics SRPT announced positive three-year top-line data from Part 1 of the phase III EMBARK study, evaluating Elevidys in ambulatory individuals with Duchenne muscular dystrophy (DMD) ...